Integrated Absolute And Relative Bioavailability Case Analysis

Putting Three Routes or Formulations Into One Case

An intravenous (IV) treatment, an oral-reference formulation, and an oral-test formulation answer related but distinct questions. The IV data provide a reference for systemic exposure after the administered dose has entered the circulation. Comparing an oral formulation with that reference estimates absolute bioavailability. Comparing the test formulation with the oral reference estimates relative bioavailability. A single case can calculate both, but the estimates do not establish the same thing.

For the calculations below, AUC denotes the relevant estimate of total concentration-time exposure, such as AUC from zero to infinity when that is the intended endpoint. This tutorial treats each AUC as already calculated; it does not address how to construct an AUC from concentration samples. The central task is to compare exposure per unit dose, while checking whether that comparison has a defensible interpretation.

Definition: Let $D_{\mathrm{IV}}$, $D_R$, and $D_T$ denote the IV, oral-reference, and oral-test doses, and let $\mathrm{AUC}_{\mathrm{IV}}$, $\mathrm{AUC}_R$, and $\mathrm{AUC}_T$ denote their corresponding exposure estimates. Absolute bioavailability for an oral formulation is $$ F_{\mathrm{abs}}=\frac{\mathrm{AUC}_{\mathrm{oral}}/D_{\mathrm{oral}}}{\mathrm{AUC}_{\mathrm{IV}}/D_{\mathrm{IV}}}. $$ Relative bioavailability of the test formulation versus the reference is $$ F_{\mathrm{rel}}=\frac{\mathrm{AUC}_T/D_T}{\mathrm{AUC}_R/D_R}. $$ Both quantities are dimensionless. They are usually reported as fractions or percentages.

The dose-normalized AUC has units of concentration-time per unit dose. Taking a ratio of two dose-normalized AUCs cancels those units. If the doses are equal within a comparison, the dose terms cancel algebraically; if they are unequal, they must remain in the calculation. A larger raw AUC alone does not show that a formulation has greater bioavailability when its administered dose is also larger.

Why the Ratios Have This Interpretation

Under linear pharmacokinetics with clearance that is unchanged across the treatments being compared, systemic exposure can be represented as

\mathrm{AUC}=\frac{F D}{CL}.

Here $F$ is the fraction of the administered dose reaching systemic circulation, $D$ is dose, and $CL$ is systemic clearance. For an IV dose, $F=1$ by definition: the dose enters the circulation directly. Substituting this relation for oral and IV exposure gives the absolute-bioavailability expression:

\frac{\mathrm{AUC}_{\mathrm{oral}}/D_{\mathrm{oral}}}{\mathrm{AUC}_{\mathrm{IV}}/D_{\mathrm{IV}}} = \frac{F_{\mathrm{oral}}/CL}{1/CL} = F_{\mathrm{oral}}.

For two oral formulations, if systemic clearance is the same, it cancels in their ratio as well:

\frac{\mathrm{AUC}_T/D_T}{\mathrm{AUC}_R/D_R} = \frac{F_T/CL}{F_R/CL} = \frac{F_T}{F_R}.

This cancellation is the justification for interpreting the ratio as relative systemic availability. It does not mean the formulations have identical absorption rates or concentration-time profiles. Nor does an oral estimate of $F_{\mathrm{abs}}$ identify which processes determine the fraction reaching circulation: absorption and presystemic loss can both contribute.

The interpretation depends on assumptions. The compared exposures should refer to the same analyte and a comparable total-exposure endpoint. Pharmacokinetics should be sufficiently linear over the doses used, and clearance should not change between periods or formulations. The IV and oral observations should be appropriately comparable in population, condition, and time; in a crossover, periods should not be distorted by carryover or other period effects. Dose and AUC records must be accurate, and the AUC estimate should adequately represent the intended exposure. These conditions support interpretation; the ratio itself cannot verify them.

Worked Example: Absolute and Relative Availability in One Case

In a hypothetical case, a participant receives an IV dose of 100 mg, an oral-reference dose of 200 mg, and an oral-test dose of 150 mg in separate, suitably washed-out periods. The corresponding total AUC estimates are 20, 32, and 24 mg·h/L. Assume for this calculation that the AUC endpoints are comparable, the measurements are reliable, and clearance is unchanged and pharmacokinetics are linear across these doses.

Step 1: Normalize each exposure by dose.

\frac{\mathrm{AUC}_{\mathrm{IV}}}{D_{\mathrm{IV}}} =\frac{20\ \mathrm{mg\cdot h/L}}{100\ \mathrm{mg}} =0.200\ \mathrm{h/L},

\frac{\mathrm{AUC}_R}{D_R} =\frac{32\ \mathrm{mg\cdot h/L}}{200\ \mathrm{mg}} =0.160\ \mathrm{h/L}, \qquad \frac{\mathrm{AUC}_T}{D_T} =\frac{24\ \mathrm{mg\cdot h/L}}{150\ \mathrm{mg}} =0.160\ \mathrm{h/L}.

Step 2: Calculate absolute bioavailability. For the reference formulation,

F_{\mathrm{abs},R} =\frac{0.160\ \mathrm{h/L}}{0.200\ \mathrm{h/L}} =0.800=80.0\%.

For the test formulation, the same IV denominator applies:

F_{\mathrm{abs},T} =\frac{0.160\ \mathrm{h/L}}{0.200\ \mathrm{h/L}} =0.800=80.0\%.

Step 3: Calculate relative bioavailability.

F_{\mathrm{rel}} =\frac{0.160\ \mathrm{h/L}}{0.160\ \mathrm{h/L}} =1.00=100\%.

In this hypothetical case, dose-normalized exposure is the same for the two oral formulations, and each oral estimate is 80.0% of the IV dose-normalized exposure. These are descriptive estimates under the stated assumptions. The matching point estimates do not, by themselves, establish bioequivalence or show that the profiles have the same shape.

Reading the Results When Doses Differ

Unequal doses are not inherently a problem: the formulas account for them. The important requirement is that dose normalization be appropriate. In particular, proportionality of exposure to dose should be credible over the range being compared. If exposure rises nonproportionally because pharmacokinetics are nonlinear, dividing AUC by dose does not generally remove the dose effect.

Worked Example: A Higher Raw AUC Does Not Mean Higher Availability

Consider a second hypothetical case with an IV dose of 75 mg and AUC of 15 mg·h/L, a reference oral dose of 150 mg and AUC of 21 mg·h/L, and a test oral dose of 300 mg and AUC of 45 mg·h/L. Suppose the same-analyte, comparable-endpoint, reliable-measurement, linearity, and unchanged-clearance conditions are judged reasonable.

The dose-normalized IV exposure is

15/75=0.200\ \mathrm{h/L}.

The reference and test dose-normalized exposures are

21/150=0.140\ \mathrm{h/L}, \qquad 45/300=0.150\ \mathrm{h/L}.

Thus, the absolute estimates are

F_{\mathrm{abs},R}=0.140/0.200=0.700=70.0\%, \qquad F_{\mathrm{abs},T}=0.150/0.200=0.750=75.0\%.

The relative estimate is

F_{\mathrm{rel}}=0.150/0.140=1.071=107.1\%.

The test has a 7.14% higher dose-normalized AUC point estimate than the reference in this case. Its raw AUC is more than twice the reference AUC, but its dose is also twice as large. It would be incorrect to interpret the raw-AUC ratio $45/21$ as the relative availability. The result remains descriptive: no uncertainty interval or population-level conclusion has been calculated.

Assumption Checks, Diagnostics, and Alternatives

A sound case analysis states both the numerical result and the conditions that give it meaning. Useful checks include the following:

Design comparability: confirm that the IV and oral periods use the same analyte and an exposure endpoint suited to the intended comparison. Consider period, sequence, and carryover concerns in a crossover, or differences between groups in a non-crossover design.
Dose and data integrity: verify administered doses, units, formulation labels, and the correspondence between each AUC and its treatment. A unit mismatch or swapped treatment label directly changes the ratio.
Exposure adequacy: check whether the supplied AUC estimates represent comparable portions of exposure. An incomplete or poorly estimated total AUC can bias either comparison; a ratio cannot repair a weak input estimate.
Linearity and clearance: inspect whether the doses span a range where dose-normalized exposure is reasonably stable, and whether time-varying physiology, interactions, or other treatment differences could alter clearance. Strong dose-related changes in AUC per unit dose are a warning that simple normalization may fail.
Individual-level variation: in a multi-participant study, a ratio of group arithmetic means is not generally the same as the mean of individual ratios. The analysis target and summary method should match the study design; one representative calculation should not be presented as a population estimate.

Absolute and relative availability are complementary, not interchangeable. Absolute bioavailability uses an IV reference and addresses how much systemic exposure an oral dose produces relative to an IV dose. Relative bioavailability compares two non-IV formulations and can be calculated without IV data. If an IV arm is unavailable, absolute availability cannot be obtained from the oral-reference and oral-test data alone, though their relative comparison may still be possible.

The dose-normalized AUC ratio is the relevant alternative to comparing raw AUCs when doses differ and linearity is supportable. If doses are equal, the raw AUC ratio and dose-normalized AUC ratio coincide algebraically, but the assumptions and interpretation still matter. A different exposure summary, such as peak concentration, answers a different question and should not be substituted silently for AUC in these definitions.

Worked Example: When Dose Normalization Is Not Enough

Suppose a hypothetical case reports an IV dose of 100 mg with AUC 10 mg·h/L, an oral-reference dose of 100 mg with AUC 8 mg·h/L, and an oral-test dose of 200 mg with AUC 20 mg·h/L. Mechanical calculation gives dose-normalized exposures of 0.100, 0.080, and 0.100 h/L, respectively. The resulting arithmetic is

F_{\mathrm{abs},R}=0.080/0.100=80.0\%, \qquad F_{\mathrm{abs},T}=0.100/0.100=100\%, \qquad F_{\mathrm{rel}}=0.100/0.080=125\%.

These values are correctly calculated from the supplied numbers, but their usual availability interpretation requires linear pharmacokinetics across the doses. Here the oral doses differ twofold, and there is no evidence supplied that dose-normalized exposure is stable over that range. If exposure is nonlinear, a difference in dose-dependent disposition could contribute to the observed ratio. The data alone therefore do not justify saying that the test formulation has 25% greater systemic availability. The appropriate conclusion is that the arithmetic ratios are 100% and 125%, while their interpretation as availability comparisons is uncertain until dose proportionality and clearance comparability are supported.

What the Case Does and Does Not Establish

A point estimate of $F_{\mathrm{rel}}=1$ means that the calculated dose-normalized AUCs are equal for the data being summarized. It does not mean that every participant has a ratio of one, that the population ratio is known without uncertainty, or that the formulations are bioequivalent. A bioequivalence conclusion requires an appropriate study design and statistical assessment of uncertainty against prespecified acceptance criteria; equality of rounded point estimates is not that assessment.

Similarly, an absolute estimate below 100% is consistent with lower systemic exposure per unit oral dose than per unit IV dose under the model assumptions. It is not a direct measurement of the fraction absorbed from the gut alone. Values above 100% should prompt checks of dose, AUC, design comparability, and assumptions rather than automatic rejection or an unqualified claim of more than complete absorption.

Common pitfall: “The test AUC is larger, so the test has higher bioavailability.” This reasoning ignores dose. Compare $\mathrm{AUC}/D$ for each treatment first, then form the ratio. Also state whether the assumptions needed to interpret that ratio are credible; a computed number is not, by itself, evidence that those assumptions hold.

Check Your Understanding

Use the definitions above. The short solutions are included so you can check both the arithmetic and the interpretation.

An IV dose of 50 mg gives AUC 10 mg·h/L. An oral dose of 100 mg gives AUC 12 mg·h/L. Calculate absolute bioavailability.
A reference dose of 200 mg gives AUC 30 mg·h/L, and a test dose of 100 mg gives AUC 18 mg·h/L. Calculate relative bioavailability.
Why is a larger raw AUC for a formulation not sufficient evidence of greater availability when doses differ?
A calculated relative-bioavailability point estimate is 100%. Name one conclusion this supports and one it does not support.

Solutions. (1) IV dose-normalized AUC is $10/50=0.200$ h/L, and oral dose-normalized AUC is $12/100=0.120$ h/L. Thus $F_{\mathrm{abs}}=0.120/0.200=0.600$, or 60.0%, assuming comparable exposure endpoints, linear pharmacokinetics, and unchanged clearance. (2) Reference exposure per dose is $30/200=0.150$ h/L; test exposure per dose is $18/100=0.180$ h/L. Therefore $F_{\mathrm{rel}}=0.180/0.150=1.20$, or 120%, subject to the relevant assumptions. (3) A higher dose can produce a higher raw AUC even when exposure per unit dose is unchanged; dose-normalize before comparing. (4) It supports equality of the summarized dose-normalized AUC point estimates in that calculation. It does not, by itself, establish population equivalence or bioequivalence, because uncertainty and prespecified criteria have not been assessed.